Stockscreener 앱 받기
4.04
1.51%
0.06
전일 마감가:
$3.98
열려 있는:
$3.97
하루 거래량:
202.27K
Relative Volume:
0.69
시가총액:
$238.15M
수익:
-
순이익/손실:
$-72.89M
주가수익비율:
-1.6694
EPS:
-2.42
순현금흐름:
$-68.47M
1주 성능:
-0.49%
1개월 성능:
-37.65%
6개월 성능:
-65.65%
1년 성능:
-61.71%
1일 변동 폭
$3.925
$4.1764
1주일 범위
$3.925
$4.39
52주 변동 폭
$3.555
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
명칭
Astria Therapeutics Inc
전화
617-349-1971
주소
22 BOSTON WHARF ROAD, BOSTON
ATXS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
4.04 | 238.15M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-29 | 개시 | TD Cowen | Buy |
| 2023-03-28 | 개시 | Evercore ISI | Outperform |
Astria Therapeutics Inc 주식(ATXS)의 최신 뉴스
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Vanguard Group Inc. - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by American Century Companies Inc. - Defense World
KLP Kapitalforvaltning AS Takes Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Raymond James Financial Inc. Takes $707,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Long Term Trading Analysis for (ATXS) - news.stocktradersdaily.com
Teacher Retirement System of Texas Makes New Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 - BioSpace
Astria Therapeutics Grants $235K Worth of Stock Options to Strategic New Hires - Stock Titan
Analysts Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $26.60 - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Swiss National Bank - Defense World
Charles Schwab Investment Management Inc. Increases Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
(ATXS) Investment Report - news.stocktradersdaily.com
What is Lifesci Capital’s Forecast for ATXS FY2025 Earnings? - The AM Reporter
Lifesci Capital Has Pessimistic View of ATXS FY2025 Earnings - Defense World
What is HC Wainwright’s Forecast for ATXS Q1 Earnings? - Defense World
Q1 EPS Forecast for Astria Therapeutics Decreased by Analyst - Defense World
Astria Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
(ATXS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Astria Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Astria Therapeutics price target raised to $28 from $27 at Wedbush - TipRanks
Wedbush Adjusts Price Target on Astria Therapeutics to $28 From $27, Keeps Outperform Rating - Marketscreener.com
Astria Therapeutics (NASDAQ:ATXS) Given Buy Rating at HC Wainwright - Defense World
Astria Therapeutics Advances Clinical Trials and Financials - TipRanks
Astria Therapeutics: Promising Developments and Strategic Advancements Justify Buy Rating - TipRanks
Astria Therapeutics, Inc. SEC 10-K Report - TradingView
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - BioSpace
Astria Therapeutics: Promising Pipeline and Strong Financials Drive Buy Rating - TipRanks
Preclinical data reported for Astria’s anti-OX40 monoclonal antibody - BioWorld Online
Astria Therapeutics posts marginally smaller-than-expected quarterly net loss per share - Marketscreener.com
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Acquired by New York State Common Retirement Fund - Defense World
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $25.67 - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
Astria Therapeutics Issues 87,450 Stock Options: What This Means for Shareholder Dilution - Stock Titan
Learn to Evaluate (ATXS) using the Charts - news.stocktradersdaily.com
Astria Therapeutics’ (ATXS) “Buy” Rating Reiterated at HC Wainwright - Defense World
Astria Therapeutics (ATXS) Projected to Post Earnings on Monday - Defense World
HC Wainwright Reaffirms "Buy" Rating for Astria Therapeutics (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics (ATXS) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Press Release From Business Wire: Astria Therapeutics, Inc. - UrduPoint News
Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema - Business Wire
Can Astria's Navenibart Change the Game for HAE Patients? Phase 3 Trial Begins After 95% Attack Reduction - Stock Titan
Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference - Business Wire
Can Astria Therapeutics' Conference Appearance Signal New Developments in Allergic Disease Treatments? - Stock Titan
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Yahoo Finance
When the Price of (ATXS) Talks, People Listen - Stock Traders Daily
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress - Business Wire
Astria Therapeutics (NASDAQ:ATXS) Shares Pass Below Fifty Day Moving Average – What’s Next? - Defense World
Astria Therapeutics: A High-Conviction Bet On HAE - Seeking Alpha
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.67 Consensus Price Target from Analysts - Defense World
Astria Therapeutics Inc (ATXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.51%
자본화:
|
볼륨(24시간):